Collaborations - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands |
1 Months Ended |
9 Months Ended |
12 Months Ended |
|
Jul. 31, 2018 |
Mar. 31, 2019 |
Mar. 31, 2021 |
Mar. 31, 2020 |
Mar. 31, 2019 |
Jul. 31, 2021 |
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Payment of stock issuance costs |
|
|
$ 232
|
|
$ 394
|
|
| Related party transactions revenue recognized |
|
|
39,917
|
$ 26,749
|
9,514
|
|
| Contract with customers liability current |
|
|
71,255
|
84,090
|
|
|
| Contract with customers liability non current |
|
|
|
3,374
|
|
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Aggregate receivables by the company pursuant to the agreement |
|
$ 400,000
|
|
|
400,000
|
|
| Temporary equity fair value |
|
272,700
|
|
|
272,700
|
|
| Performance obligation transaction price |
|
127,300
|
|
|
127,300
|
|
| Cumulative payments received |
|
|
75,000
|
|
|
|
| Related party transactions revenue recognized |
|
|
39,900
|
26,700
|
9,500
|
|
| Contract with customers liability current |
|
|
30,100
|
41,700
|
|
|
| Contract with customers liability non current |
|
|
0
|
3,400
|
|
|
| Performance obligation revenue recognized |
|
|
|
2,600
|
|
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] | Accounts Payable and Accrued Liabilities [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Payable towards reimbursement of shared costs |
|
|
11,500
|
7,800
|
|
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] | Research and Development Expense [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Expenditure Incurred Pursuant To Cost Sharing Agreements |
|
|
18,700
|
19,100
|
6,300
|
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] | Cost of Sales [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Expenditure Incurred Pursuant To Cost Sharing Agreements |
|
|
$ (1,400)
|
$ 1,000
|
(200)
|
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] | Annual Payment One [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Annual payment receivable by the company |
|
25,000
|
|
|
25,000
|
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] | Annual Payment Two [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Annual payment receivable by the company |
|
25,000
|
|
|
25,000
|
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] | Annual Payment Three [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Annual payment receivable by the company |
|
25,000
|
|
|
25,000
|
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] | Annual Payment Four [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Annual payment receivable by the company |
|
25,000
|
|
|
25,000
|
$ 25,000
|
| Glaxosmithkline Agreement [Member] | Glaxosmith Kline [Member] | Series F Redeemable Preferred Stock [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Temporary equity shares issued during the period shares |
17,291,066
|
|
|
|
|
|
| Proceeds from redeemable preferred stock net |
$ 299,600
|
|
|
|
|
|
| Temporary equity issue price per share |
$ 17.35
|
|
|
|
|
|
| Payment of stock issuance costs |
$ 400
|
|
|
|
|
|
| Proceeds from redeemable preferred stock net |
|
300,000
|
|
|
|
|
| Almirall Agreement [Member] | Almirall [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Performance obligation transaction price |
|
2,700
|
|
|
2,700
|
|
| Almirall Agreement [Member] | Almirall [Member] | One Time Payment [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Performance obligation transaction price |
|
2,500
|
|
|
2,500
|
|
| Almirall Agreement [Member] | Almirall [Member] | Payment Over Agreement Term [Member] |
|
|
|
|
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
| Performance obligation transaction price |
|
$ 200
|
|
|
$ 200
|
|